BCMA Targeted Therapies
Evvnt Promotion / evvnt
Archive
21.06.2021 - 23.06.2021 Online
Time: 09:00 - 16:00
Conference themes
Targeting BCMA with therapeutics such as ADCs, bispecific T-cell engagers (BiTEs) and CAR-T therapies within Multiple Myeloma has huge potential. The race for an approval within the crowded BCMA space has been hotly contested in recent years, and despite GSK's ADC, Blenrep, gaining approval in 2020 first, BCMA-targeted CAR-T and BiTe therapies continue to find their place.
Targeting BCMA with therapeutics such as ADCs, bispecific T-cell engagers (BiTEs) and CAR-T therapies within Multiple Myeloma has huge potential. The race for an approval within the crowded BCMA space has been hotly contested in recent years, and despite GSK's ADC, Blenrep, gaining approval in 2020 first, BCMA-targeted CAR-T and BiTe therapies continue to find their place.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Notes
Speakers: Adam Cohen, Assistant Professor - Medicine, University of Pennsylvania, Andreas Pahl, Chied Scientific Officer, Heidelbeg Pharma, David DiLillo, Assoc. Director, Immuno-Oncology, Regeneron and more.
Speakers: Adam Cohen, Assistant Professor - Medicine, University of Pennsylvania, Andreas Pahl, Chied Scientific Officer, Heidelbeg Pharma, David DiLillo, Assoc. Director, Immuno-Oncology, Regeneron and more.
Enquiries and Registration:
https://go.evvnt.com/727512-2?pid=4832
Mr. Customer Service
General Medicine
Languages
English
English
Congress fees
USD 1799.0 - USD 3237.0
USD 1799.0 - USD 3237.0
Participants expected
1000
1000
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."
